Genmab A-S

Yahoo Finance • 14 days ago

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; Decemb... Full story

Yahoo Finance • 15 days ago

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 202... Full story

Yahoo Finance • 16 days ago

BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appoint... Full story

Yahoo Finance • 16 days ago

Dow Jones Stock Caterpillar In Buy Zone After Recent Breakout Move

Dow Jones stock Caterpillar is in a buy zone following a recent breakout move as the stock market indexes rally near record highs. Continue Reading... Full story

Yahoo Finance • 17 days ago

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Media Release COPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a t... Full story

Yahoo Finance • 18 days ago

Genmab : Phase 3 Trial Shows EPKINLY + R2 Cuts Progression Risk By 79% And Achieves 95% ORR In FL

(RTTNews) - Genmab A/S (GMAB) announced primary results from the pivotal Phase 3 EPCORE FL-1 study, evaluating fixed-duration EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) in adult patients with r... Full story

Yahoo Finance • 19 days ago

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Media Release COPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2)resulted in statistically significant and clinically meaningful reduction in the... Full story

Yahoo Finance • 19 days ago

Genmab Reports Promising Clinical Trial Results For Fixed-Duration Epcoritamab In Lymphoma

(RTTNews) - Genmab A/S (GMAB) announced updated findings from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered, T-cell engaging antibody. The data highlight the potential of epcoritamab as both m... Full story

Yahoo Finance • 20 days ago

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Media Release COPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPC... Full story

Yahoo Finance • 20 days ago

AI Plays Lead Five Stocks To Watch Near Buy Points

Artificial intelligence, data center and energy plays highlight this week's list of stocks to watch. Taiwan Semiconductor and Vertiv Holdings have rebounded near buy points following concerns over an AI bubble. Nuclear play Constellation E... Full story

Yahoo Finance • 21 days ago

How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter

Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus. Continue Reading... Full story

Yahoo Finance • 22 days ago

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously announced offering of $1.... Full story

Yahoo Finance • 24 days ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; December 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of th... Full story

Yahoo Finance • last month

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants to employees of the Company and the Compa... Full story

Yahoo Finance • last month

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of t... Full story

Yahoo Finance • last month

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility

Media Release COPENHAGEN, Denmark; November 18, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have priced their previously announced offering of $1... Full story

Yahoo Finance • last month

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,059 shares as a consequence of the exercise of employee warrants. The increase is effected without any preempti... Full story

Yahoo Finance • last month

AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images * The U.S. Food and Drug Administration (FDA) on Tuesday announced the approval of Epkinly, a bispecific antibody developed by AbbVi... Full story

Yahoo Finance • last month

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line settingIn the Phase 3 EPCORE® FL-1 trial, fixed dura... Full story

Yahoo Finance • 2 months ago

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, subject to market and other conditio... Full story